Senate grants the FDA a 6.5% raise in funding

Share this article:
The FDA's total funding for FY 2007 has been set at $1.942 billion--representing a 6.5%
increase over the previous year. The Senate Appropriations Committee reported out the agency's spending provision as part of the agriculture appropriations bill.

The measure includes “increases of $50.5 million for pandemic avian influenza preparedness, $8.6 million for medical device and animal drug review, $4.0 million for drug safety, $5.5 million for food safety, $10.0 million for generic drug review, $5.9 million for the Critical Path initiative, and $2.5 million for human tissue safety,” a committee release said.

It noted that the bill does not include language addressing the FDA's authority to require post-marketing studies of drugs, a provision dropped by the House when it passed its version in May.

The bill does, however, include language representing a compromise agreement requiring the FDA to provide advance notification about conflicts of interest waivers granted to outside experts impaneled as “special government employees” on FDA advisory committees, 15 days prior to committee meetings.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.